Know what makes sense? What about making a two for one drug, combining Mimetogen's and TB 4 together. Both are totally safe. Both are naturally ocuring. Both just turbo charge what is already there. Mimetogen fialed it's phase 2 primary for OVERALL cornea. RGRX failed in it's Phase 2 primary - ONLY the INFERIOR region of cornea. But Mimetgen got good results in the INFERIOR region of cornea, but not overall cornea. Conversely, RGRX didn't do well in INFERIOR cornea, but got over the top P values in the CENTRAL and SUPERIOR regions of te cornea.....places where Mimetogen drug flopped.. Multiple combination drugs are used all the time in many doseasse areas (look at HCV). And often with bad side effects. Neither Mimetigen or RGRX drug has any safety or side effect issues..and where each drug worked or flopped, the others didn't. TB 4 and Mimetogen drugs combined compliment response. - just going off what I see on the phase 2 results - would be a category killer drug.in a $1 billion market. But don't hold your breath. Finkelstein is in charge here, Someone should contact George Ousler at ORA Inc....he did BOTH Mimetohen and TB 4 trials...and he worked with Bausch & Lomb, I'm sure.. Someone should clue in Finkelstein too.